As of 2025-11-15, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -9.20 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 10.20 GBP, the upside of ImmuPharma PLC is -190.22%.
Based on its market price of 10.20 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 190.22%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -9.20 - -9.20 | -9.20 | -190.22% |
| P/E | (9.05) - (9.89) | (11.33) | -211.1% |
| DDM - Stable | (3.83) - (9.90) | (6.86) | -167.3% |
| DDM - Multi | (2.00) - (4.21) | (2.73) | -126.8% |
| Market Cap (mil) | 52.79 |
| Beta | 0.41 |
| Outstanding shares (mil) | 5.18 |
| Enterprise Value (mil) | 52.39 |
| Market risk premium | 5.98% |
| Cost of Equity | 14.41% |
| Cost of Debt | 5.00% |
| WACC | 9.43% |